Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lumateperone

lumateperone

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of lumateperone

5 trials tracked of lumateperone: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 113 citations.

5Trials tracked
5Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 5
  1. Phase 3 Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally Completed · 113 cited
  2. Phase 3 Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder Completed · 21 cited
  3. Phase 3 Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Completed · 8 cited
  4. Phase 3 Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Completed
  5. Phase 3 An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Lumateperone 42 mg plus ADT improves MADRS scores in MDD with anxious distress
Drug Pipeline RCT
Lumateperone 42 mg plus ADT improves MADRS scores in MDD with anxious distress Lumateperone May Help Depression and Anxiety in Specific Patients
This post hoc analysis of a Phase 3 randomized trial evaluated 481 outpatients with MDD and inadequate response to 1-2 ADTs. Lumateperone 42…
A study suggests adding lumateperone to standard treatment may improve depression and anxiety symptoms for patients with anxious distress.
Sep 21, 2026
Lumateperone 42mg plus ADT reduces MADRS score by 22.9 in treatment-resistant MDD
Drug Pipeline RCT
Lumateperone 42mg plus ADT reduces MADRS score by 22.9 in treatment-resistant MDD Trial shows lumateperone helps adults with major depressive disorder
This Phase 3 open-label extension study of 809 adults with MDD and inadequate response to 1-2 ADTs found lumateperone 42mg plus ADT signific…
A new trial shows that adding lumateperone to standard antidepressants may improve symptoms for adults with major depressive disorder.
Sep 18, 2026
Lumateperone adjunct therapy improves sexual functioning in patients with major depressive disorder
Psychiatry RCT
Lumateperone adjunct therapy improves sexual functioning in patients with major depressive disorder New medication helps sexual function in patients with depression
This study evaluated the impact of adding lumateperone to standard antidepressant therapy for adults with major depressive disorder who had …
A new treatment for depression may help patients regain sexual function that is often lost during standard antidepressant treatments.
Sep 9, 2026
Xanomeline/trospium chloride associated with greater odds of clinical response than several second-generation antipsychotics
Psychiatry Sys. Review
Xanomeline/trospium chloride associated with greater odds of clinical response than several second-generation antipsychotics New schizophrenia treatment shows fewer weight gains than common drugs
This network meta-analysis of 14,680 adults with schizophrenia compared xanomeline/trospium chloride (KarXT) against eight second-generation…
A new drug combination for schizophrenia may offer better weight management and symptom control compared to several common antipsychotic med…
Aug 1, 2026
FDA Approves Caplyta (lumateperone) for Schizophrenia in Adults
Psychiatry FDA Approval
FDA Approves Caplyta (lumateperone) for Schizophrenia in Adults FDA approves Caplyta to treat schizophrenia in adults
FDA approved Caplyta (lumateperone) for treatment of schizophrenia in adults.
The FDA approved Caplyta (lumateperone) for treating schizophrenia in adults.
FDA Apr 29, 2026